Introduction to Drusen and AMD Risk

The presence of drusen represents a risk factor for AMD progression, with progression dependent on drusen characteristics, genetic susceptibility, and modifiable risk factors, particularly smoking status, according to the American Academy of Ophthalmology 1, 2
Large drusen (≥125 μm), bilateral soft drusen, and confluent drusen represent high-risk features that significantly increase progression risk, as stated by the American Academy of Ophthalmology 1, 2

Critical Modifiable and Non-Modifiable Risk Factors

Age remains the dominant risk factor, with AMD prevalence increasing from 1% in those aged 65-69 to 17% in those older than 80, as reported by the National Eye Institute 3
Family history and genetic polymorphisms strongly influence whether drusen progress to advanced disease, according to the American Academy of Ophthalmology 1, 3
Cigarette smoking is the single most critical modifiable risk factor, with current smokers facing 2-3 times higher AMD risk and progression proportional to pack-years smoked, as stated by the American Heart Association 2, 3
Cardiovascular disease, elevated BMI, and hyperlipidemia correlate with higher progression risk, as reported by the American College of Cardiology 3
Poor diet and nutrition contribute to AMD development in patients with drusen, according to the Academy of Nutrition and Dietetics 1, 4

For patients with intermediate AMD, initiate AREDS2 supplementation immediately to reduce progression risk by up to 36% over 10 years, as recommended by the National Eye Institute 2, 4
Risk stratification based on drusen characteristics is crucial, with bilateral large drusen (≥125 μm) with RPE clumping or atrophy considered high risk, and AREDS2 supplementation should be started, according to the American Academy of Ophthalmology 1, 2
Mandatory smoking cessation counseling is necessary at every visit, as this is the only proven modifiable risk factor that prevents progression, as stated by the American Lung Association 2, 3
The AREDS2 formulation specifics include vitamin C, vitamin E, zinc 25mg, copper, lutein 10mg, and zeaxanthin 2mg, as recommended by the National Eye Institute 2
Patient education on self-monitoring is essential, with provision of an Amsler grid for daily home monitoring of metamorphopsia, and instruction to return immediately for any new visual symptoms, as recommended by the American Academy of Ophthalmology 2

Patients presenting with large bilateral soft drusen (≥125 µm) and associated retinal pigment epithelium (RPE) alterations are classified as having intermediate or advanced age‑related macular degeneration (AMD). 5, 6

Drusen that are ≥125 µm in size, bilateral, soft or confluent are pathognomonic for AMD and indicate disease presence. 5, 6
RPE changes—including atrophy, hyper‑pigmentation, or thickening—signal progression of AMD. 5, 6
The appearance of geographic atrophy or choroidal neovascularization (e.g., sub‑retinal hemorrhage, fluid, or lipid deposits) denotes advanced AMD. 6, 7

In individuals with intermediate AMD (large drusen with RPE changes) or unilateral advanced AMD, daily supplementation with the AREDS2 formulation (vitamin C, vitamin E, zinc 25 mg, copper, lutein 10 mg, and zeaxanthin 2 mg) is associated with prevention of disease progression and vision loss in a population exceeding 300 000 patients. 6, 7

Counseling to cease smoking at every clinical encounter is essential, as smoking is the only modifiable risk factor proven to reduce AMD progression; the risk of progression rises proportionally with cumulative pack‑years. Evidence from ophthalmology studies supports the critical impact of immediate smoking cessation. 6, 8

Early AMD is typically asymptomatic; therefore, routine fundus examination is required for individuals with known risk factors to enable timely detection. 6, 7
Initiating anti‑VEGF therapy promptly after diagnosis of neovascular (wet) AMD is linked to a more favorable visual prognosis compared with delayed treatment. 6